Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (71-80 of 740) with videos related to

Pageof 74
Sort By:
Onkologie|June 5, 2010
Avascular osteonecrosis of the jaw as a side effect of bisphosphonate treatmentAristotle Bamias, Evangelos Terpos, Meletios A Dimopoulos
Clinical Lymphoma, Myeloma & Leukemia|April 9, 2013
Proteasome inhibitor therapy for Waldenström's macroglobulinemiaMeletios A Dimopoulos, Evangelos Terpos, Efstathios Kastritis
The New England Journal of Medicine|December 24, 2016
Daratumumab and Blood-Compatibility TestingMeletios A Dimopoulos, Pieter Sonneveld, Huabin Sun
Expert Review of Hematology|February 4, 2014
Staging and prognostication of multiple myelomaRafael Fonseca, Jorge Monge, Meletios A Dimopoulos
Current Hematologic Malignancy Reports|April 19, 2018
How We Manage Patients with PlasmacytomasDespina Fotiou, Meletios A Dimopoulos, Efstathios Kastritis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Advances in imaging and the management of myeloma bone diseaseEvangelos Terpos, Lia A Moulopoulos, Meletios A Dimopoulos
The Lancet. Oncology|July 31, 2025
Unpublished overall survival confounders in immunomodulatory agent registrational trials - Authors' replyJesus San-Miguel, Paul Richardson, Meletios A Dimopoulos
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016Evangelos Terpos, Meletios A Dimopoulos, Lia A Moulopoulos
Expert Review of Hematology|October 19, 2018
Prognostic factors for multiple myeloma in the era of novel therapiesDimitrios C Ziogas, Meletios A Dimopoulos, Efstathios Kastritis
Cancer Journal (Sudbury, Mass.)|January 30, 2019
Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple MyelomaIoannis Ntanasis-Stathopoulos, Evangelos Terpos, Meletios A Dimopoulos
Pageof 74

Showing results (71-80 of 740) with videos related to

Sort By:
Pageof 74
Onkologie|June 5, 2010
Avascular osteonecrosis of the jaw as a side effect of bisphosphonate treatmentAristotle Bamias, Evangelos Terpos, Meletios A Dimopoulos
Clinical Lymphoma, Myeloma & Leukemia|April 9, 2013
Proteasome inhibitor therapy for Waldenström's macroglobulinemiaMeletios A Dimopoulos, Evangelos Terpos, Efstathios Kastritis
The New England Journal of Medicine|December 24, 2016
Daratumumab and Blood-Compatibility TestingMeletios A Dimopoulos, Pieter Sonneveld, Huabin Sun
Expert Review of Hematology|February 4, 2014
Staging and prognostication of multiple myelomaRafael Fonseca, Jorge Monge, Meletios A Dimopoulos
Current Hematologic Malignancy Reports|April 19, 2018
How We Manage Patients with PlasmacytomasDespina Fotiou, Meletios A Dimopoulos, Efstathios Kastritis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Advances in imaging and the management of myeloma bone diseaseEvangelos Terpos, Lia A Moulopoulos, Meletios A Dimopoulos
The Lancet. Oncology|July 31, 2025
Unpublished overall survival confounders in immunomodulatory agent registrational trials - Authors' replyJesus San-Miguel, Paul Richardson, Meletios A Dimopoulos
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016Evangelos Terpos, Meletios A Dimopoulos, Lia A Moulopoulos
Expert Review of Hematology|October 19, 2018
Prognostic factors for multiple myeloma in the era of novel therapiesDimitrios C Ziogas, Meletios A Dimopoulos, Efstathios Kastritis
Cancer Journal (Sudbury, Mass.)|January 30, 2019
Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple MyelomaIoannis Ntanasis-Stathopoulos, Evangelos Terpos, Meletios A Dimopoulos
Pageof 74